论文部分内容阅读
目的观察斯奇康联合化学药物治疗复治及耐多药肺结核的近期及远期效果。方法311例涂阳病人随机分为治疗组及对照组,两组化疗方案相同,治疗组加用斯奇康(卡介菌多糖核酸)。结果复治治疗组痰菌转阴率81.03%,2年复发率6.4%;对照组分别为61.8%、24.2%。耐多药治疗组痰菌转阴率58.3%,2年复发率16.7%;对照组分别为9.4%、60%。经统计学处理皆有显著差异(P<0.05)。结论治疗组疗效明显优于对照组,卡介菌多糖核酸辅助治疗复治及耐多药肺结核可明显提高近期及远期治疗效果。
Objective To observe the short-term and long-term effects of combined treatment of schistosomiasis and multi-drug resistant pulmonary tuberculosis. Methods A total of 311 smear positive patients were randomly divided into treatment group and control group. The chemotherapy regimens of the two groups were the same, and the treatment group was given STK (BCG - PSN). Results The rate of sputum negative conversion in retreatment group was 81.03%, and the recurrence rate in 2 years was 6.4%. The control group was 61.8% and 24.2% respectively. The multidrug-resistant group sputum bacilli conversion rate was 58.3%, 2-year recurrence rate was 16.7%; control group were 9.4%, 60%. Statistical analysis showed significant differences (P <0.05). Conclusion The treatment group was significantly better than the control group, BCG-assisted nucleic acid adjuvant therapy and multi-drug resistant pulmonary tuberculosis can significantly improve the short-term and long-term treatment.